Romark, a research-based pharmaceutical company, has started a phase three clinical trial of its investigational new drug candidate, NT-300, intended for the treatment of mild or moderate COVID-19, it was reported on Tuesday.

The trial is to study up to 800 subjects, twelve years of age and older, with fever and respiratory symptoms consistent with COVID-19. The subjects will be administered either NT-300 or placebo twice daily for five days.

The study's primary endpoint is the decrease in the time to sustained response compared with placebo, and the secondary endpoint is a decrease in the rate of progression to severe COVID-19 illness compared with placebo.